O Shaughnessy Asset Management LLC Sells 13,096 Shares of Boston Scientific Corporation $BSX

O Shaughnessy Asset Management LLC reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 4.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 276,989 shares of the medical equipment provider’s stock after selling 13,096 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Boston Scientific were worth $26,411,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Murphy & Mullick Capital Management Corp lifted its stake in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Colonial Trust Co SC increased its position in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares during the last quarter. Bangor Savings Bank raised its holdings in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund bought a new stake in Boston Scientific in the 4th quarter worth approximately $29,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 9,800 shares of company stock worth $554,012 over the last quarter. Corporate insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on BSX. Weiss Ratings lowered Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Bank of America cut their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Finally, UBS Group decreased their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $85.92.

Boston Scientific Stock Performance

NYSE:BSX opened at $48.73 on Tuesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a fifty-two week low of $47.17 and a fifty-two week high of $109.50. The firm has a market cap of $72.42 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 0.91 and a beta of 0.56. The business has a 50 day moving average price of $57.68 and a 200-day moving average price of $76.17.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has approved a share buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.